India, April 8 -- Caris Life Sciences (CAI) has introduced a new multimodal, AI-driven molecular insight designed to help determine whether certain non-small cell lung cancer patients benefit from adding chemotherapy- or may actually be harmed by it.
Non-small cell lung cancer (NSCLC) is the most common form of lung cancer and a leading cause of cancer-related deaths. For patients whose tumors are driver-negative and express high levels of PD-L1 (=50%), physicians often choose between immunotherapy alone or a combination of immunotherapy and chemotherapy. While chemotherapy can improve outcomes for some, it may reduce survival for others, making treatment decisions challenging.
Caris' new AI-powered signature was developed using its large...